| Revenue growth | 21.8% YoY |
|---|---|
| Margins | Declining: EBITDA margin 3.5% vs 4.7% YoY |
| Demand visibility | Strong pharmacy demand; Diagnostics growing 22.4% |
| Management confidence | Moderate; tracking 99% of AOP revenue |
Growth
Revenue grew 21.8% YoY; Pharmacy segment up 21.8% and Diagnostics up 22.4%. PAT declined 21.7% YoY.
Outlook
Added 146 stores in Q1; total network at 5,476. Planned FY27 Capex of ₹1,977.6M for expansion.
Risks
Gross margin compression (160 bps YoY) due to lower Private Label sales mix and lower franchisee margins.
Last quarter's promises, checked
Delivered
- Guided 9-10% SSSG → delivered 17.8% (= BEAT)
- Guided 30-33 day warehouse inventory → delivered 30 days (= BEAT)
Partly delivered
- Guided 800 net new stores for FY27 → delivered 146 in Q1 (= PARTIAL)
Missed
- Guided 5.7-5.8% EBITDA margin → delivered 3.5% (= MISS)
Investor Presentation filed with NSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹654.90
- Market cap
- ₹7,868 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 37.4×Sector 57.8×
- Promoter holding
- 40.19%-0.03% QoQ
- FII holding
- 14.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.
- Value
- ₹0.01 Cr
- From
- Drugs Control Administration, Haveri Circle, Karnataka
Medplus Health Services Legal & Regulatory
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
- Value
- ₹0.01 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
- Value
- ₹0.02 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
- Value
- ₹0.10 Cr
Medplus Health Services Adverse Business Impact
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Execution
- 7 days
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
- Value
- ₹0.10 Cr
- Execution
- 5 to 15 days